Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by C2N Diagnostics
C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology
Today 18:34 EDT
From
C2N Diagnostics
Via
Business Wire
Alzheimer’s Disease Community Benefits as C2N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard
August 02, 2023
From
C2N Diagnostics
Via
Business Wire
C2N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment1,2, Is Poised to Support Medical Community in Next Steps
July 06, 2023
From
C2N Diagnostics
Via
Business Wire
C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion
April 24, 2023
From
C2N Diagnostics
Via
Business Wire
C2N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023
April 04, 2023
From
C2N Diagnostics
Via
Business Wire
International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference
November 17, 2022
From
C2N Diagnostics
Via
Business Wire
C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health
September 21, 2022
From
C2N Diagnostics
Via
Business Wire
C2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia
August 30, 2022
From
C2N Diagnostics
Via
Business Wire
Tickers
ASX:HLS
C2N’s New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment
July 31, 2022
From
C2N Diagnostics
Via
Business Wire
C2N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field
May 18, 2022
From
C2N Diagnostics
Via
Business Wire
JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease
April 21, 2022
From
C2N Diagnostics
Via
Business Wire
C2N Achieves ISO 13485:2016 Certification; Latest Development for Leader in Brain Health Sector
February 22, 2022
From
C2N Diagnostics
Via
Business Wire
Researchers to Present Multiple Studies at CTAD and GSA Meetings About the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnoses
November 05, 2021
From
C2N Diagnostics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.